Result of AGM

RNS Number : 6466U

Syncona Limited

02 August 2022

 

Syncona Limited

Result of Annual General Meeting

2 August 2022

At the Annual General Meeting of Syncona Limited (the "Company") held today, all Resolutions as set out in the 'Notice of the 2022 Annual General Meeting' dated 30 June 2022 sent to shareholders of the Company (the "Notice") were duly passed.

Resolutions 1 to 12 were proposed as Ordinary Resolutions. Resolution 13 was proposed as a Special Resolution and Resolution 14 was proposed as an Extraordinary Resolution.

Details of the proxy voting results, which should be read alongside the Notice, are noted below:

No	Resolution	For	Discretion	Against	Abstain (withheld)
1	Receive and consider the Annual Audited Financial Statements of the Company for the year ended 31 March 2022, together with the Reports of the Directors and Auditors thereon	464,372,350 (99.96%)	(0) (0%)	189,929 (0.04%)	7,875
2	Re-appointment of Deloitte LLP (Guernsey Branch) as Auditors	464,325,349 (99.99%)	(0) (0%)	53,133 (0.01%)	191,672
3	Authorise the Directors to determine the remuneration of the Auditors	464,558,338 (99.99%)	(0) (0%)	9,578 (0.01%)	2,238
4	Re-elect Melanie Gee as a Director	463,062,580 (99.68%)	(0) (0%)	1,490,199 (0.32%)	17,375
5	Elect Julie Cherrington as a Director	464,536,562 (99.99%)	(0) (0%)	4,217 (0.01%)	29,375
6	Elect Cristina Csimma as a Director	464,536,562 (99.99%)	(0) (0%)	4,217 (0.01%)	29,375
7	Re-elect Virginia Holmes as a Director	463,062,580 (99.68%)	(0) (0%)	1,490,199 (0.32%)	17,375
8	Re-elect Rob Hutchinson as a Director	463,029,675 (99.67%)	(0) (0%)	1,523,104 (0.33%)	17,375
9	Re-elect Kemal Malik as a Director	463,020,330 (99.67%)	(0) (0%)	1,523,104 (0.33%)	26,720
10	Re-elect Gian Piero Reverberi as a Director	463,028,580 (99.67%)	(0) (0%)	1,521,854 (0.33%)	19,720
11	Approve the report on implementation of the Remuneration Policy for Non-Executive Directors	463,065,971 (99.68%)	(0) (0%)	1,475,563 (0.32%)	28,620
12	Authority to allot and issue shares	464,193,797 (99.93%)	(0) (0%)	346,067 (0.07%)	30,290
13	Authorise the Company to purchase its own shares	464,346,845 (99.95%)	(0) (0%)	211,264 (0.05%)	12,045
14	Disapply pre-emption rights	456,459,320 (98.26%)	(0) (0%)	8,088,893 (1.74%)	21,941

A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.

In accordance with the Listing Rule 9.6.2, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the Financial Conduct Authority via the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

The full text of the resolutions can be found in the Notice, which is available on the Company's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/ .

Enquiries

Syncona Limited
Natalie Garland-Collins / Fergus Witt

Tel: [phone]

FTI Consulting

Ben Atwell / Julia Bradshaw / Tim Stamper

Tel: [phone]

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com .

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building a portfolio of global leaders in life science to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

 

END

 

 

RAGUPUQPRUPPGGP